/Viatris%20Inc%20logo%20on%20building-by%20SSKH-Pictures%20via%20Shutterstock.jpg)
With a market cap of $9.1 billion, Viatris Inc. (VTRS) is a global healthcare company with a portfolio of over a thousand approved molecules, including brands like EpiPen, Lipitor, and Viagra, and biosimilars such as pegfilgrastim, trastuzumab, and adalimumab. Operating across Developed Markets, Greater China, JANZ, and Emerging Markets, it offers medicines across major therapeutic areas and partners with Mapi Pharma, Revance Therapeutics, and Theravance Biopharma.
The Canonsburg, Pennsylvania-based company is expected to release its fiscal Q1 2025 earnings results before the market opens on Thursday, May 8. Ahead of this event, analysts expect VTRS to report an adjusted EPS of $0.52, down 22.4% from $0.67 in the prior year's quarter. It has surpassed Wall Street's bottom-line estimates in two of the past four quarters while missing on two occasions.
